In Vitro Assay for Chemical Allergens

过敏性接触性皮炎(ACD)是世界上最常见和最昂贵的健康问题之一 工业化国家。目前，有100,000多种化学品在商业上使用， 另有2,000种新化学品和许多新产品配方被测试或销售 每年都有。所有这些材料都必须进行过敏性筛查。 在第一阶段，开发了一种基于人树突状细胞的检测方法，该方法可以给出敏感的 以及对过敏原的特定反应。未优化的化验结果大约少了10倍。 比目前基于动物的测试更昂贵。此外，该检测还避免了动物福利问题 以及与物种外推有关的不确定性。在第二阶段，测试的材料数据库 将进行扩展，并最终确定体外检测方法和预测模型。这个 将对分析的重复性进行评估，并在实验室间演示后 可转移性，将进行多实验室GLP验证研究。最后，一种优化的检测试剂盒 从而进一步增强了体外培养方法的经济优势。 变态反应性接触性皮炎，体外试验，浆细胞样树突状细胞。用于评估化学品的变态反应性接触性皮炎可能性的预测测试系统将具有 在化妆品、个人卫生和局部药物等行业中的广泛应用 产品。过敏性评估对于将职业和公众的危害降至最低很重要 接触化学品和产品。拟议的基于人体细胞的检测将提供一种灵敏和 无需使用实验室动物且成本较低的特定过敏原筛选方法。

Allergic contact dermatitis (ACD) is one of the most common and costly health problems in industrialized countries. Currently, more than 100,000 chemicals are in commercial use and another 2,000 new chemicals and numerous new-product formulations are tested or marketed every year. All of these materials must be screened for allergenicity. During Phase I, a human dendritic cell based assay was developed which gives sensitive and specific responses to allergens. The non-optimized assay is approximately a factor of 10 less expensive than current animal based tests. In addition, the assay avoids animal welfare issues and uncertainty related to species extrapolation. During Phase II, thedatabase of materials tested will be expanded and the in vitro assay method and prediction model will be finalized. The reproducibility of the assay will be assessed and, after demonstration of interlaboratory transferability, a multi-lab GLP validation study will be performed. Finally, an optimized assay kit which further enhances the economic advantages of the in vitro method will be developed. Allergic contact dermatitis, in vitro testing, plasmacytoid DC. A predictive test system for assessing the allergic contact dermatitis potential of chemicals will have far reaching application in industries involved in cosmetic, personal hygiene and topical pharmaceutical products. Evaluation of allergenicity is important to minimize the hazards of occupational and public exposure to chemicals and products. The proposed human cell based assay will provide a sensitive and specific method of allergen screening without the use of laboratory animals and at a reduced cost.